001     127794
005     20240228140950.0
024 7 _ |a 10.18632/oncotarget.3377
|2 doi
024 7 _ |a pmid:25749049
|2 pmid
024 7 _ |a pmc:PMC4466681
|2 pmc
037 _ _ |a DKFZ-2017-03816
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Williams, Richard D
|b 0
245 _ _ |a Multiple mechanisms of MYCN dysregulation in Wilms tumour.
260 _ _ |a [S.l.]
|c 2015
|b Impact Journals LLC
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1508923398_22424
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Genomic gain of the proto-oncogene transcription factor gene MYCN is associated with poor prognosis in several childhood cancers. Here we present a comprehensive copy number analysis of MYCN in Wilms tumour (WT), demonstrating that gain of this gene is associated with anaplasia and with poorer relapse-free and overall survival, independent of histology. Using whole exome and gene-specific sequencing, together with methylation and expression profiling, we show that MYCN is targeted by other mechanisms, including a recurrent somatic mutation, P44L, and specific DNA hypomethylation events associated with MYCN overexpression in tumours with high risk histologies. We describe parallel evolution of genomic copy number gain and point mutation of MYCN in the contralateral tumours of a remarkable bilateral case in which independent contralateral mutations of TP53 also evolve over time. We report a second bilateral case in which MYCN gain is a germline aberration. Our results suggest a significant role for MYCN dysregulation in the molecular biology of Wilms tumour. We conclude that MYCN gain is prognostically significant, and suggest that the novel P44L somatic variant is likely to be an activating mutation.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Proto-Oncogene Proteins c-myc
|2 NLM Chemicals
650 _ 7 |a TP53 protein, human
|2 NLM Chemicals
650 _ 7 |a Tumor Suppressor Protein p53
|2 NLM Chemicals
700 1 _ |a Chagtai, Tasnim
|b 1
700 1 _ |a Alcaide-German, Marisa
|b 2
700 1 _ |a Apps, John
|b 3
700 1 _ |a Wegert, Jenny
|b 4
700 1 _ |a Popov, Sergey
|b 5
700 1 _ |a Vujanic, Gordan
|b 6
700 1 _ |a van Tinteren, Harm
|b 7
700 1 _ |a van den Heuvel-Eibrink, Marry M
|b 8
700 1 _ |a Kool, Marcel
|0 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
|b 9
|u dkfz
700 1 _ |a de Kraker, Jan
|b 10
700 1 _ |a Gisselsson, David
|b 11
700 1 _ |a Graf, Norbert
|b 12
700 1 _ |a Gessler, Manfred
|b 13
700 1 _ |a Pritchard-Jones, Kathy
|b 14
773 _ _ |a 10.18632/oncotarget.3377
|g Vol. 6, no. 9, p. 7232 - 7243
|0 PERI:(DE-600)2560162-3
|n 9
|p 7232 - 7243
|t OncoTarget
|v 6
|y 2015
|x 1949-2553
909 C O |o oai:inrepo02.dkfz.de:127794
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|2 G:(DE-HGF)POF3-300
|v Functional and structural genomics
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2015
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ONCOTARGET : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ONCOTARGET : 2015
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l Pädiatrische Neuroonkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21